Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.30 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: regorafenib | 1.00 |
| trials ClinicalTrials.gov | 6 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 4 Parkinson's papers of 707 | 0.79 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 1254
Sealed predictions
- DDR2 in dopamine neurons, braak+0.08 (p 0.838) → +0.24 (p 0.529)receipt 1260
Swarm cases
receipt 1260: DDR2 in dopamine neurons, braak
- power
- full sample +0.16 (p 0.515, n 18), 95% CI -0.33 to +0.59. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.19 (p 0.439, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.20 (p 0.434, n 18). could be the mix.
- skeptic
- leave-one-out range +0.05 to +0.26, sign flips 0; without severely affected donors +0.16 (p 0.515, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DDR2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts